Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
DPP-4 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
DPP-4 Inhibitors Market: Competitive Landscape, Pipeline, and Market Analysis 2023
DPP-4 (Dipeptidyl Peptidase - 4) is an enzyme that is widely expressed throughout the body and abundantly expressed in endothelial cells. DPP-4 inhibition is a glucose-lowering treatment for type 2 diabetes. DPP-4 inhibitors act by inhibiting DPP-4 activity in peripheral plasma, which prevents the inactivation of incretin hormone glucagon-like peptide (GLP)-1 in the peripheral circulation, which in turn increases circulating intact GLP-1, resulting in stimulated insulin secretion and inhibited glucagon secretion, thereby increasing glucose utilization and reducing hepatic glucose production, which then through the reduction in postprandial and fasting glucose, reduces HbA1c. Merck (MSD), Takeda Pharmaceutical, Boehringer Ingelheim, Novartis, Eli Lilly, AstraZeneca, and Pfizer are some of the major market players in the diabetes segment with DPP-4 inhibitors in the market. Moreover, these companies also have DPP-4 inhibitors in their pipeline for more targeted therapy.
Key Market Developments:
Approved Drug Molecules and Brand Names for DPP-4 Inhibitors:
Drugs under the Pipeline for DPP-4 Inhibitors:
Clinical Activity and Developments of DPP-4 Inhibitors:
Currently, there are about 65 drug products, including 26 marketed products and more than 30 products in clinical trials in the DPP-4 inhibitors.
|
Molecule Name |
Number of Studies |
|
Retagliptin (SP2086) |
18 |
|
Dutogliptin (PHX1149T) |
15 |
|
Talabostat (BXCL701) |
14 |
|
Prusogliptin (DBPR108) |
12 |
|
Janacti (Sitagliptin/Pioglitazone) |
6 |
|
HSK7653 |
5 |
|
Satyor (Gosogliptin) |
4 |
|
ZemiStatin (Gemigliptin/Rosuvastatin FDC) |
4 |
|
Trijardy XR (Empagliflozin/Linagliptin) |
3 |
|
ZemiSU (Gemigliptin/Glimepiride) |
3 |
|
Alogliptin Metformin extended release (CT-L01) |
3 |
|
Linagliptin/Pioglitazone |
3 |
|
Begedina (Begelomab) |
2 |
|
KRP-104 |
2 |
|
Qternmet XR (Dapagliflozin/Saxagliptin) |
2 |
|
Dapagliflozin/Sitagliptin (SID1903) |
2 |
|
Fotagliptin (SAL067) |
2 |
|
IP10 C8 |
1 |
|
TQ-F3083 |
1 |
|
YS110 |
1 |
|
ZYDPLA1 |
1 |
|
Besigliptin (SHR117887) |
1 |
|
Dapagliflozin/Linagliptin (IN-C009) |
1 |
|
Dapagliflozin/Metformin/Sitagliptin (GMRx4) |
1 |
|
Dapagliflozin/Sitagliptin (DW6012) |
1 |
|
Enavogliflozin/Gemigliptin (DWJ1563) |
1 |
|
Glimepiride/Vildagliptin/Metformin (GVM) |
1 |
|
Melogliptin (GRC 8200) |
1 |
|
Metformin/Retagliptin (HRX0701) |
1 |
|
Sitagliptin /Atorvastatin (MK-0431E) |
1 |
DPP-4 inhibitors are a class of prescription medicines that are used with diet and exercise to control high blood sugar in adults with type 2 diabetes mellitus. Additionally, DPP-4 inhibitors have also been marketed for cardiovascular disorders like chronic heart failure, renal failure, and type 1 diabetes mellitus. Bristol-Myers Squibb and AstraZeneca’s Dapagliflozin is in phase-III clinical trial for COVID-19 infections, heart failure, and myocardial infarction, and in phase-I trial for kidney disorders, liver cirrhosis, obesity, and pre-diabetic state. ADIENNE’s Begelomab is in phase-II/III for graft-versus-host disease, and phase-II for dermatomyositis
Merck (MSD)’s Januvia (Sitagliptin) and Janumet (Sitagliptin/ Metformin HCl) sales declined 34% to US$ 913 million in 2022 from US$ 1,393 million in 2021, primarily reflecting generic competition in certain international markets, particularly in Europe and the APAC region, and lower demand and net pricing in the USA. Novartis’s Glavus (Vildagliptin)’s sales declined to US$ 859 in the year 2022 due to lower sales in Japan, Europe, and Emerging growth markets. Boehringer Ingelheim’s Tradjenta (Linagliptin) will see all of its patent expiration by Mar 2031. Based on the World Health Organization’s 2020 data, overall, 243.3 million males and 229.0 million females worldwide had diabetes, where the age-standardized prevalence of diabetes was highest in Oceania, high-income North America, North Africa, the Middle East, and Central America.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
G JANUVIA (Sitagliptin), GALVUS (Vildagliptin), TRADJENTA (Linagliptin), ONGLYZA (Saxagliptin), NESINA (Alogliptin), JANUMET (Metformin/Sitagliptin) are the some of the approved drugs in the DPP-4 Inhibitors.
Total sale of Glavus (Vildagliptin) was US$ 859 in the year 2022.
Merck (MSD), Takeda Pharmaceutical, Boehringer Ingelheim, Novartis, Eli Lilly, AstraZeneca, and Pfizer are some of the major market players in the DPP-4 inhibitors market.
Type 2 diabetes mellitus is the major indication of DPP-4 inhibitors.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.